Oral peptide pills getting real FDA love, but the delivery tech matters more than the hype
Posted by patient_codes in Research & News - 0 points, 4 comments.
MedCity News had a piece on Pinnacle Medicines raising $89M to push oral peptides that they claim hit like injectable biologics, especially for asthma and COPD. The article talks about how the FDA just greenlit the first peptide pills for obesity and plaque psoriasis, which is honestly a bigger deal than most people realize. Pills that act like injectables could change compliance for a lot of patients who hate needles.
My take is that the molecule is only half the story, the delivery tech is where the real work is. Stomach acid and gut lining chew up most peptides before they do anything, so any company saying they cracked that without showing real bioavailability data is just fundraising. I'd want to see the actual pharmacokinetic numbers before I get excited.
Has anyone here followed the oral GLP-1 story closely enough to know if the absorption is actually holding up in patients, or just in press releases? ðŸ§
Comments
- tiredmira: Honestly the absorption question is the whole game here. Novo's oral semaglutide works because of the SNAC carrier, not because the peptide magically survives stomach acid on its own. Without that kind of absorption enhancer, I basically don't believe any oral peptide claim I see. Pinnacle's pitch sounds familiar though. Raise money, talk up a platform, promise bioavailability later. I've been burned enough times tracking my own numbers to know press release numbers and actual blood levels live
- patient_codes: I totally get that, the carrier makes or breaks it. I tried an oral BPC-157 once without any enhancer and saw nothing in my recovery logs, but when I used a version with SNAC-like tech my gut felt noticeably better after a week 😅. Real PK data is the only thing that’ll convince me.
- weekendnate: Yeah SNAC is the only reason oral sema works at all, that part isn't debatable. The carrier is doing the heavy lifting and the molecule just tags along for the ride. Pinnacle's press cycle does have that fundraising smell to it though. Without PK curves I can't tell if I'm reading science or just a pitch deck.
- patient_codes: Yeah exactly, SNAC doing the heavy lifting is the point. The molecule gets all the credit in the press releases but the carrier is what's actually solving the gut problem. And you're right, without the PK curves it really is just a pitch deck ðŸ§
Community discussion - research and educational context only. Not medical advice.